<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Edwin P Hui, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anthony TC Chan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Bruce E Brockstein, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David M Brizel, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marvin P Fried, MD, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Melinda Yushak, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 20, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nasopharyngeal carcinoma is the predominant tumor type arising in the nasopharynx, the tubular passage behind the nasal cavity that connects to the oropharynx below  (
         <a class="graphic graphic_figure graphicRef97306" href="/z/d/graphic/97306.html" rel="external">
          figure 1
         </a>
         ). It differs from other head and neck squamous cell carcinomas in epidemiology, histology, natural history, and response to treatment.
        </p>
        <p>
         This topic discusses the epidemiology, etiology, diagnosis, and staging of nasopharyngeal carcinoma. The pathology and treatment of nasopharyngeal carcinoma are presented elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3372.html" rel="external">
          "Treatment of early and locoregionally advanced nasopharyngeal carcinoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3381.html" rel="external">
          "Treatment of recurrent and metastatic nasopharyngeal carcinoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3375.html" rel="external">
          "Pathology of head and neck neoplasms"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Worldwide, there were over 133,000 new cases and 80,000 deaths due to nasopharyngeal carcinoma [
         <a href="#rid1">
          1
         </a>
         ]. Nasopharyngeal carcinoma displays a distinct racial and geographic distribution, which is reflective of its multifactorial etiology [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Geographic and ethnic distribution
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of nasopharyngeal carcinoma demonstrates marked geographic variation. It is rare in the United States and Western Europe, with an incidence of 0.5 to 2 cases per 100,000 [
         <a href="#rid3">
          3,4
         </a>
         ]. By contrast, nasopharyngeal carcinoma is endemic in Southern China, including Hong Kong, where the incidence may reach 25 cases per 100,000 per year. Intermediate-risk regions include Southeast Asia, North Africa and the Middle East, and the Arctic. Populations that migrate from areas of high risk to areas of low risk retain an elevated risk, although this risk typically diminishes in successive generations [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Sex and age distribution
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of nasopharyngeal carcinoma is two- to threefold higher in males compared with in females.
        </p>
        <p>
         In high-risk populations, the incidence peaks around 50 to 59 years of age and declines thereafter. There is also a minor incidence peak observed among adolescents and young adults in Southeast Asia, the Middle East/North Africa, and the United States. In most low-risk populations, nasopharyngeal carcinoma incidence increases with age [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Secular trend
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of nasopharyngeal carcinoma has declined over the past 30 years in many endemic areas, including Hong Kong, Singapore, and Taiwan [
         <a href="#rid5">
          5-7
         </a>
         ]. The reasons for this decline are unclear, although they are generally attributed to lifestyle changes associated with the rapid economic development that occurred in these areas. As an example, there has been a decrease in the use of salted fish to feed infants and reduced exposure to traditional preserved food. However, the declining incidence may also be due to population shifts as a result of altered immigration patterns.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          ETIOLOGY AND RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The geographic variation of nasopharyngeal carcinoma incidence suggests a multifactorial etiology. In endemic populations, risk appears to be due to an interaction of several factors: Epstein-Barr virus (EBV) infection, environmental factors (such as the high intake of preserved foods and smoking), and genetic predisposition [
         <a href="#rid8">
          8
         </a>
         ]. Furthermore, the increased incidence in younger adults in high- and intermediate-risk areas suggests that exposure to a common agent early in life is a critical factor [
         <a href="#rid3">
          3
         </a>
         ]. In the United States and Europe, nasopharyngeal carcinoma is more commonly associated with alcohol and tobacco use, which are classic risk factors for other head and neck tumors [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H308758431">
         <span class="h2">
          Epstein-Barr virus
         </span>
         <span class="headingEndMark">
          —
         </span>
         A large body of evidence supports the role of EBV as a primary etiologic agent in the pathogenesis of nasopharyngeal carcinoma [
         <a href="#rid10">
          10
         </a>
         ]. This includes the detection of both EBV deoxyribonucleic acid (DNA) and EBV gene expression in precursor lesions and tumor cells. Nasopharyngeal carcinoma cells express a specific subgroup of EBV-latent proteins, including EBNA1 (Epstein-Barr virus nuclear antigen 1) and two integral membrane proteins, LMP1 (latent membrane protein 1) and LMP2 (latent membrane protein 2), along with the BamHI-A fragment of the EBV genome. Patients with nasopharyngeal carcinoma also demonstrate specific serologic responses to various gene products of EBV, particularly immunoglobulin A antibodies directed against the EBV viral capsid antigen. (See
         <a class="medical medical_review" href="/z/d/html/8276.html" rel="external">
          "Virology of Epstein-Barr virus"
         </a>
         .)
        </p>
        <p>
         Smoking has also been associated with nasopharyngeal carcinoma and may be involved in the pathogenesis of nasopharyngeal carcinoma by causing EBV reactivation [
         <a href="#rid11">
          11,12
         </a>
         ].
        </p>
        <p>
         The association of nasopharyngeal carcinoma with EBV infection has been exploited to develop noninvasive diagnostic tests. It is also being used experimentally to treat advanced disease. (See
         <a class="local">
          'Screening based on Epstein-Barr virus testing'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/3372.html" rel="external">
          "Treatment of early and locoregionally advanced nasopharyngeal carcinoma", section on 'Is there a role for EBV DNA in posttreatment surveillance?'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3381.html" rel="external">
          "Treatment of recurrent and metastatic nasopharyngeal carcinoma", section on 'Investigational agents'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3621861257">
         <span class="h2">
          Human papillomavirus
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of human papillomavirus (HPV) as an etiologic agent for nasopharyngeal carcinoma is less well defined than that of EBV, and its relative frequency may differ substantially in endemic and nonendemic regions.
        </p>
        <p>
         In a study of 1328 patients with nonkeratinizing, undifferentiated (type III) nasopharyngeal carcinoma from Hong Kong and Southeast China, EBV RNA was detected in 91.5 percent of cases, while HPV (measured using polymerase chain reaction and p16 immunohistochemistry, with 100 percent concordance) was present in 7.7 percent [
         <a href="#rid13">
          13
         </a>
         ]. Co-infection was rare (less than 1 percent). The prognosis for patients with HPV-associated nasopharyngeal carcinoma was significantly better on a stage-by-stage basis than the prognosis for patients whose disease was associated with EBV.
        </p>
        <p>
         In nonendemic, low-incidence regions, HPV infection is the same or more common, as a percent of total cases, compared with in endemic areas, with a similar or worse outcome than with EBV-related nasopharyngeal carcinoma. However, HPV-associated nasopharyngeal carcinoma is not well characterized in this setting [
         <a href="#rid14">
          14,15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Diet
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several dietary practices in endemic areas are thought to contribute to the high incidence of nasopharyngeal carcinoma [
         <a href="#rid8">
          8,16
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The cooking of salt-cured food, which releases volatile nitrosamines that are carried by steam and distributed over the nasopharyngeal mucosa.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Early childhood exposure to salted fish, which was traditionally used for weaning.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High consumption of preserved or fermented foods (including meats, eggs, fruits, and vegetables), which contain high levels of nitrosamines as well as bacterial mutagens, direct genotoxins, and EBV-reactivating substances.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The use of Chinese medicinal herbs, which may contribute either by reactivating EBV or through a direct promoting effect on EBV-transformed cells.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The consumption among the Maghrebian population from Tunisia, Algeria, and Morocco of rancid butter and sheep's fat, which contain butyric acid, a potential EBV activator and causative agent for nasopharyngeal carcinoma.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Heredity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genetic factors may influence the risk of nasopharyngeal carcinoma [
         <a href="#rid8">
          8
         </a>
         ]. One case-control study, for example, suggested that having a first-degree relative with nasopharyngeal carcinoma increased risk sevenfold [
         <a href="#rid17">
          17
         </a>
         ]. With evidence for clustering within families, some have recommended screening for first-degree relatives of patients with nasopharyngeal carcinoma [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="local">
          'Screening based on Epstein-Barr virus testing'
         </a>
         below.)
        </p>
        <p>
         Nasopharyngeal carcinoma has been associated with certain HLA (human leukocyte antigen) haplotypes [
         <a href="#rid19">
          19-22
         </a>
         ]. Nasopharyngeal carcinoma has also been associated with genetic polymorphisms, such as CYP2A6 (cytochrome P450 2A6), which is a polymorphism of a nitrosamine-metabolizing gene [
         <a href="#rid23">
          23,24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Molecular pathogenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Development of nasopharyngeal carcinoma involves virologic, genetic, and environmental factors, as shown in the etiologic studies. A collaborative model for nasopharyngeal carcinoma pathogenesis driven by specific genetic alterations and EBV-latent infection has been proposed. Multiple chromosomal abnormalities (eg, copy number changes on chromosomes 3p, 9p, 11q, 12p, and 14q), gene alterations (eg, p16 deletion and LTBR [lymphotoxin-beta receptor] amplification), and epigenetic changes (eg, RASSF1A [Ras association domain family 1 isoform A] and TSLC1 [tumor suppressor in lung cancer 1] methylation) have been identified by various genome-wide approaches. Studies on the precancerous lesions and in vitro immortalized nasopharyngeal epithelial cell models provide important evidence for the involvement of genetic alterations and EBV infection in early development of this cancer, and critical genetic events contribute to the initiation and progression of nasopharyngeal carcinoma [
         <a href="#rid25">
          25,26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8276.html" rel="external">
          "Virology of Epstein-Barr virus", section on 'Biology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1596986148">
         <span class="h1">
          HISTOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nasopharyngeal carcinoma arises from the epithelial lining of the nasopharynx.
        </p>
        <p>
         The World Health Organization (WHO) classifies nasopharyngeal carcinoma into three histopathologic types [
         <a href="#rid4">
          4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Keratinizing squamous cell carcinoma
         </strong>
         – The sporadic form of nasopharyngeal carcinoma is most commonly the keratinizing subtype (WHO type I).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonkeratinizing carcinoma
         </strong>
         – This is subdivided into differentiated (WHO type II) and undifferentiated (WHO type III) forms. The endemic form of nasopharyngeal carcinoma is commonly the undifferentiated, nonkeratinizing subtype (WHO type III); this is strongly associated with Epstein-Barr virus (EBV) and has a more favorable prognosis than other types.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Basaloid squamous cell carcinoma
         </strong>
         – Basaloid squamous cell carcinoma was added to the WHO classification of head and neck tumors in 2005. There are few reported cases, but they are notable for an aggressive clinical course and poor survival [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In North America, the relative frequencies of the different histologic subtypes are 25 percent keratinizing (type I), 12 percent differentiated (type II), and 63 percent undifferentiated (type III). By contrast, the histologic distribution among Southern Chinese patients is 2 percent keratinizing, 3 percent differentiated, and 95 percent undifferentiated [
         <a href="#rid28">
          28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3375.html" rel="external">
          "Pathology of head and neck neoplasms"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common presenting complaints in patients with nasopharyngeal carcinoma are headache, diplopia, or facial numbness, caused by cranial nerve involvement, and a mass in the neck, due to cervical node metastases [
         <a href="#rid8">
          8
         </a>
         ]. The clinical triad of neck mass, nasal obstruction with epistaxis, and serous otitis media occurs infrequently, although each of these symptoms occurs commonly in patients with nasopharyngeal carcinoma. Otitis media in an adult without a prior history of this condition should raise suspicion for nasopharyngeal carcinoma, especially if the patient is of an ethnicity with a high incidence of this disease.
        </p>
        <p>
         Nasopharyngeal carcinoma frequently originates from the pharyngeal recess, the fossa of Rosenmüller. Since this is a clinically occult site, patients may remain asymptomatic for a prolonged period. The majority of patients present with locally and/or regionally advanced disease because of this prolonged asymptomatic period or, in some cases, due to a missed diagnosis [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         The primary tumor may present as a smooth submucosal fullness, a discrete nodule with or without surface ulceration, or an infiltrative fungating mass. Erosion into the skull base is common with or without involvement of cranial nerves [
         <a href="#rid29">
          29
         </a>
         ]. Cranial nerves III, IV, V, and VI are most commonly affected because of paracavernous sinus tumor invasion [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         Nasopharyngeal carcinoma has a tendency for early metastatic spread [
         <a href="#rid31">
          31-33
         </a>
         ]. Lymph node metastases are present at diagnosis in 75 to 90 percent of cases and are bilateral in over 50 percent. Distant metastases are present at diagnosis in 5 to 11 percent of patients.
        </p>
        <p>
         The location and extent of lymph node metastases are predictive of distant metastases [
         <a href="#rid34">
          34,35
         </a>
         ]. The most frequent sites of distant metastases are the bone (75 percent), lung, liver, and distant nodes [
         <a href="#rid33">
          33
         </a>
         ]. Multiple paraneoplastic syndromes, including neutrophilia, fever of unknown origin, hypertrophic osteoarthropathy, and dermatomyositis, can occur [
         <a href="#rid33">
          33,36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          INITIAL DIAGNOSTIC EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         A definitive diagnosis is made with endoscope-guided biopsy of the primary tumor. Incisional neck biopsy or nodal dissection should be avoided as this procedure will negatively impact subsequent treatment [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         Routine evaluation should include a history and physical examination including the cranial nerves, complete blood counts, and serum biochemistry, including liver function tests and alkaline phosphatase. Other studies should include chest radiograph, nasopharyngoscopy, and computed tomography (CT) and magnetic resonance imaging (MRI) of the nasopharynx, skull base, and neck. When ordering an MRI, it is important to specifically request cranial nerve imaging, as a standard brain MRI does not provide adequate detail.
        </p>
        <p>
         We suggest obtaining pretreatment plasma Epstein-Barr virus (EBV) DNA levels as part of the diagnostic and staging evaluation. Pretreatment plasma EBV DNA levels are prognostic and have been associated with survival outcomes [
         <a href="#rid38">
          38-41
         </a>
         ]. The addition of pretreatment plasma EBV DNA to the eighth edition of the American Joint Committee on Cancer (AJCC) tumor, node, metastasis (TNM) staging system has improved its prognostic performance  (
         <a class="graphic graphic_table graphicRef110658" href="/z/d/graphic/110658.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid42">
          42,43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3372.html" rel="external">
          "Treatment of early and locoregionally advanced nasopharyngeal carcinoma", section on 'Prognosis'
         </a>
         .)
        </p>
        <p>
         Additional imaging is indicated for patients with advanced nodal disease (stage N3  (
         <a class="graphic graphic_table graphicRef110658" href="/z/d/graphic/110658.html" rel="external">
          table 1
         </a>
         )), clinical evidence suggesting distant metastases, or an EBV DNA load ≥4000 copies/mL, since these patients are at high risk for distant metastases. Fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging is the preferred modality in this setting [
         <a href="#rid8">
          8,44-46
         </a>
         ]. Because of its superior ability to detect lymph node and bone metastases, we suggest PET scanning if available [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3393.html" rel="external">
          "Overview of the diagnosis and staging of head and neck cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4170034305">
         <span class="h1">
          STAGING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nasopharyngeal carcinoma is clinically staged according to the eighth edition (2017) of the Union for International Cancer Control (UICC) and American Joint Committee on Cancer (AJCC) tumor, node, metastasis (TNM) system  (
         <a class="graphic graphic_table graphicRef110658" href="/z/d/graphic/110658.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid47">
          47
         </a>
         ]. This staging system provides important prognostic information and guidance for choosing the appropriate treatment for patients with nasopharyngeal carcinoma. (See
         <a class="medical medical_review" href="/z/d/html/3372.html" rel="external">
          "Treatment of early and locoregionally advanced nasopharyngeal carcinoma", section on 'STAGING'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          SCREENING BASED ON EPSTEIN-BARR VIRUS TESTING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the link between Epstein-Barr virus (EBV) infection and nasopharyngeal carcinoma, and the high cure rate for early-stage nasopharyngeal carcinoma, screening of high-risk populations using EBV testing has been proposed. Nevertheless, routine screening for EBV is not standard practice in most locations, with the exception of a few oncology centers in Southern China, which offer it as early detection to first-degree relatives of patients with nasopharyngeal carcinoma.
        </p>
        <p>
         The strong etiologic link between EBV infection and nasopharyngeal carcinoma is supported by abnormal anti-EBV antibody profiles, increased circulating EBV DNA levels, and distinct EBV gene expression in tumor cells. Various indicators of EBV infection have been investigated as screening strategies for nasopharyngeal carcinoma; these include EBV-specific antibody-based assays, measurement of circulating EBV DNA levels, and measurement of novel serologic biomarkers, including anti-BNLF2b (P85-Ab).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          EBV-specific antibody-based assays
         </strong>
         – In patients with nasopharyngeal carcinoma, the characteristic anti-EBV serologic profile consists of a sustained rise in antibodies to viral capsid antigen (VCA) and early antigen immunoglobulin A (IgA) [
         <a href="#rid33">
          33
         </a>
         ]. In Southern China, where nasopharyngeal carcinoma is endemic, EBV serology (ie, serum VCA/IgA or IgA/early antigen antibody titers) has been effectively used for population-based screening [
         <a href="#rid48">
          48-51
         </a>
         ]. As an example, a prospective, cluster randomized controlled trial conducted in southern China evaluated the performance of a combined VCA/EBNA1 IgA antibody score to screen for nasopharyngeal carcinoma [
         <a href="#rid51">
          51
         </a>
         ]. This study included over 70,000 subjects in the total screening group (although only approximately 30,000 subjects actually participated in screening) and approximately 50,000 in the control group. At median follow-up of six years, the early diagnostic rates of nasopharyngeal carcinoma were higher in the subjects who participated in screening (79 percent) and the total screening group (46 percent) compared with the control group (21 percent). Although the total screening group demonstrated similar nasopharyngeal carcinoma-specific mortality compared with the control group, nasopharyngeal carcinoma-specific mortality was reduced in subjects who actually participated in the screening program (RR 0.22, 95% CI 0.09-0.49).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          EBV DNA measurement
         </strong>
         – Quantitation of circulating EBV DNA has been studied as a method for nasopharyngeal carcinoma screening in an endemic area [
         <a href="#rid52">
          52-56
         </a>
         ]. In a cohort study of 20,174 participants screened using EBV DNA, with subsequent endoscopic examination and MRI for those with positive results, the sensitivity and specificity for nasopharyngeal cancer were 97 and 99 percent, respectively [
         <a href="#rid56">
          56
         </a>
         ]. Among the 19,865 individuals who initially screened negative for plasma EBV DNA, only one case of nasopharyngeal carcinoma was diagnosed in the year after screening.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A case control study in Taiwan compared EBV antibodies versus plasma EBV DNA levels as screening strategies in 819 newly diagnosed nasopharyngeal carcinoma cases and 1768 controls. Compared with EBV antibody-based testing, EBV DNA load had both a higher sensitivity (93 versus 88 percent) and specificity (98 versus 95 percent) [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Novel strategies
         </strong>
         – A retrospective study used a peptide library of EBV sequences to identify anti-BNLF2b (P85-Ab) as a possible serologic biomarker for nasopharyngeal carcinoma [
         <a href="#rid58">
          58
         </a>
         ]. In a subsequent prospective cohort in almost 25,000 participants in China, including 47 with nasopharyngeal carcinoma, P85-Ab was better than a standard two-antibody based screening method, with higher sensitivity (98 versus 72 percent), specificity (98 versus 97 percent), and positive predictive value (10 versus 4.3 percent) [
         <a href="#rid58">
          58
         </a>
         ]. Using both P85-Ab and the two-antibody method together increased the positive predictive value to 45 percent, with sensitivity of 70 percent.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Monitoring for treatment response and recurrence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Monitoring posttreatment plasma EBV DNA levels may have a role in evaluating treatment response and detecting recurrence [
         <a href="#rid59">
          59
         </a>
         ]. The sensitivity of EBV DNA in the detection of a local recurrence after radiation therapy (RT; ie, tumors regrowing from an irradiated site) is much lower than that in a radiation-naϊve site [
         <a href="#rid60">
          60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3372.html" rel="external">
          "Treatment of early and locoregionally advanced nasopharyngeal carcinoma"
         </a>
         .)
        </p>
        <p>
         Clinical outcomes are worse among patients with unfavorable plasma EBV DNA responses after induction chemotherapy [
         <a href="#rid61">
          61,62
         </a>
         ], at midcourse of RT [
         <a href="#rid63">
          63
         </a>
         ], and post-RT [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         Post-RT plasma EBV DNA has been validated as the most significant prognostic biomarker in a prospective biomarker study of 798 patients with nasopharyngeal carcinoma [
         <a href="#rid64">
          64
         </a>
         ]. Post-RT plasma EBV DNA is utilized to select high-risk patients for adjuvant therapy in ongoing clinical trials (NRG-HN001,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02135042%3Fterm%3DNCT02135042%26rank%3D1&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzh35RvrgLNrXQnXVeh%2FjIk79glKV%2Ft7dPXWv7dQn4OfR23lQIOlOnC0jmwbi4%2F%2FGc%3D&amp;TOPIC_ID=3404" target="_blank">
          NCT02135042
         </a>
         ;
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02363400&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzh35RvrgLNrXQnXVeh%2FjIkQ3D3sYccLiCmdXFMSUUhqA%3D%3D&amp;TOPIC_ID=3404" target="_blank">
          NCT02363400
         </a>
         ) [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2629191320">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/128559.html" rel="external">
          "Society guideline links: Head and neck cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anatomy
         </strong>
         – Nasopharyngeal carcinoma is an epithelial neoplasm arising in the nasopharynx  (
         <a class="graphic graphic_figure graphicRef97306" href="/z/d/graphic/97306.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Geographic distribution
         </strong>
         – Although nasopharyngeal carcinoma is rare in most parts of the world, it is endemic in southern China, Southeast Asia, North Africa, and the Arctic, where undifferentiated, nonkeratinizing squamous cell carcinoma is the predominant histology. (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="local">
          'Histology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – The major etiologic factors for endemic nasopharyngeal carcinoma are genetic susceptibility, early age exposure to chemical carcinogens, and Epstein-Barr virus (EBV) infection. (See
         <a class="local">
          'Etiology and risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Screening for nasopharyngeal carcinoma using plasma EBV DNA testing
         </strong>
         – Analysis of EBV DNA in plasma is useful for screening at-risk populations for nasopharyngeal carcinoma. It can detect the cancer at an early stage with a superior treatment outcome compared with the unscreened population. (See
         <a class="local">
          'Screening based on Epstein-Barr virus testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic evaluation
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Biopsy
         </strong>
         – For the initial diagnostic evaluation of nasopharyngeal carcinoma, we suggest endoscopically guided biopsy of the primary tumor and MRI of the nasopharynx, skull base, and neck to assess locoregional disease extent. (See
         <a class="local">
          'Initial diagnostic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Imaging studies
         </strong>
         – For patients with advanced nodal stage (N3) or clinical or biochemical evidence of distant metastases, we offer additional imaging with positron emission tomography (PET) or integrated PET/CT imaging if available. Otherwise, bone scan and CT of the chest and abdomen may be obtained. (See
         <a class="local">
          'Initial diagnostic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pretreatment plasma EBV DNA testing
         </strong>
         – We suggest obtaining pretreatment plasma EBV DNA levels for their prognostic significance. There is emerging evidence supporting serial measurement of plasma EBV DNA levels to assess treatment response or monitor for recurrence. (See
         <a class="local">
          'Initial diagnostic evaluation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/3372.html" rel="external">
          "Treatment of early and locoregionally advanced nasopharyngeal carcinoma"
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Global Cancer Observatory. International Agency for Research on Cancer. World Health Organization. Available at: https://gco.iarc.fr/ (Accessed on December 13, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma. Lancet 2019; 394:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006; 15:1765.
          </a>
         </li>
         <li class="breakAll">
          Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology and Genetics of Head and Neck Tumours. In: World Health Organization Classification of Tumors, IARC Press, Lyon 2005.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee AW, Foo W, Mang O, et al. Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20-year period (1980-99): an encouraging reduction in both incidence and mortality. Int J Cancer 2003; 103:680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu MC, Yuan JM. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 2002; 12:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu C, Shen YC, Cheng CC, et al. Difference in the incidence trend of nasopharyngeal and oropharyngeal carcinomas in Taiwan: implication from age-period-cohort analysis. Cancer Epidemiol Biomarkers Prev 2006; 15:856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chua ML, Wee JT, Hui EP, Chan AT. Nasopharyngeal carcinoma. Lancet 2016; 387:1012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaughan TL, Shapiro JA, Burt RD, et al. Nasopharyngeal cancer in a low-risk population: defining risk factors by histological type. Cancer Epidemiol Biomarkers Prev 1996; 5:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghupathy R, Hui EP, Chan AT. Epstein-Barr virus as a paradigm in nasopharyngeal cancer: from lab to clinic. Am Soc Clin Oncol Educ Book 2014; :149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu FH, Xiong D, Xu YF, et al. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation. J Natl Cancer Inst 2012; 104:1396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu WL, Chen JY, Chien YC, et al. Independent effect of EBV and cigarette smoking on nasopharyngeal carcinoma: a 20-year follow-up study on 9,622 males without family history in Taiwan. Cancer Epidemiol Biomarkers Prev 2009; 18:1218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang WB, Chan JYW, Liu DL. Human papillomavirus and World Health Organization type III nasopharyngeal carcinoma: Multicenter study from an endemic area in Southern China. Cancer 2018; 124:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dogan S, Hedberg ML, Ferris RL, et al. Human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma in a low-incidence population. Head Neck 2014; 36:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stenmark MH, McHugh JB, Schipper M, et al. Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis. Int J Radiat Oncol Biol Phys 2014; 88:580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guo X, Johnson RC, Deng H, et al. Evaluation of nonviral risk factors for nasopharyngeal carcinoma in a high-risk population of Southern China. Int J Cancer 2009; 124:2942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ung A, Chen CJ, Levine PH, et al. Familial and sporadic cases of nasopharyngeal carcinoma in Taiwan. Anticancer Res 1999; 19:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loh KS, Goh BC, Lu J, et al. Familial nasopharyngeal carcinoma in a cohort of 200 patients. Arch Otolaryngol Head Neck Surg 2006; 132:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hildesheim A, Apple RJ, Chen CJ, et al. Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 2002; 94:1780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lu CC, Chen JC, Jin YT, et al. Genetic susceptibility to nasopharyngeal carcinoma within the HLA-A locus in Taiwanese. Int J Cancer 2003; 103:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feng BJ, Huang W, Shugart YY, et al. Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat Genet 2002; 31:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu SP, Day NE, Li DR, et al. Further evidence for an HLA-related recessive mutation in nasopharyngeal carcinoma among the Chinese. Br J Cancer 2005; 92:967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tiwawech D, Srivatanakul P, Karalak A, Ishida T. Cytochrome P450 2A6 polymorphism in nasopharyngeal carcinoma. Cancer Lett 2006; 241:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cao Y, Miao XP, Huang MY, et al. Polymorphisms of XRCC1 genes and risk of nasopharyngeal carcinoma in the Cantonese population. BMC Cancer 2006; 6:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo KW, Chung GT, To KF. Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches. Semin Cancer Biol 2012; 22:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong KCW, Hui EP, Lo KW, et al. Nasopharyngeal carcinoma: an evolving paradigm. Nat Rev Clin Oncol 2021; 18:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller E, Beleites E. The basaloid squamous cell carcinoma of the nasopharynx. Rhinology 2000; 38:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005; 365:2041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King AD, Lam WW, Leung SF, et al. MRI of local disease in nasopharyngeal carcinoma: tumour extent vs tumour stage. Br J Radiol 1999; 72:734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aiken RD. Neurologic complications of head and neck cancers. Semin Oncol 2006; 33:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu MM, Tu SM. Nasopharyngeal carcinoma in Taiwan. Clinical manifestations and results of therapy. Cancer 1983; 52:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vokes EE, Liebowitz DN, Weichselbaum RR. Nasopharyngeal carcinoma. Lancet 1997; 350:1087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Altun M, Fandi A, Dupuis O, et al. Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects. Int J Radiat Oncol Biol Phys 1995; 32:859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakata K, Hareyama M, Tamakawa M, et al. Prognostic factors of nasopharynx tumors investigated by MR imaging and the value of MR imaging in the newly published TNM staging. Int J Radiat Oncol Biol Phys 1999; 43:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liao XB, Mao YP, Liu LZ, et al. How does magnetic resonance imaging influence staging according to AJCC staging system for nasopharyngeal carcinoma compared with computed tomography? Int J Radiat Oncol Biol Phys 2008; 72:1368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cvitkovic E, Bachouchi M, Boussen H, et al. Leukemoid reaction, bone marrow invasion, fever of unknown origin, and metastatic pattern in the natural history of advanced undifferentiated carcinoma of nasopharyngeal type: a review of 255 consecutive cases. J Clin Oncol 1993; 11:2434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bossi P, Chan AT, Licitra L, et al. Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol 2021; 32:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 2006; 24:5414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan AT, Lo YM, Zee B, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002; 94:1614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004; 350:2461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang W, Chen Y, Chen L, et al. The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 cases. Medicine (Baltimore) 2015; 94:e845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guo R, Tang LL, Mao YP, et al. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma. Cancer 2019; 125:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee VH, Kwong DL, Leung TW, et al. The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification. Int J Cancer 2019; 144:1713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chua ML, Ong SC, Wee JT, et al. Comparison of 4 modalities for distant metastasis staging in endemic nasopharyngeal carcinoma. Head Neck 2009; 31:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang MC, Chen JH, Liang JA, et al. Accuracy of whole-body FDG-PET and FDG-PET/CT in M staging of nasopharyngeal carcinoma: a systematic review and meta-analysis. Eur J Radiol 2013; 82:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang LQ, Chen QY, Fan W, et al. Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol 2013; 31:2861.
          </a>
         </li>
         <li class="breakAll">
          Lee AWM, Lydiatt WM, Colevas AD, et al. Nasopharynx. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), Springer, New York 2017. p.103.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zong YS, Sham JS, Ng MH, et al. Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer 1992; 69:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeng Y, Zhang LG, Wu YC, et al. Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer 1985; 36:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu Z, Ji MF, Huang QH, et al. Two Epstein-Barr virus-related serologic antibody tests in nasopharyngeal carcinoma screening: results from the initial phase of a cluster randomized controlled trial in Southern China. Am J Epidemiol 2013; 177:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ji MF, Sheng W, Cheng WM, et al. Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China. Ann Oncol 2019; 30:1630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo YM, Chan LY, Lo KW, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999; 59:1188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens SJ, Verkuijlen SA, Hariwiyanto B, et al. Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia. J Clin Microbiol 2005; 43:3066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan KC, Lo YM. Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma. Semin Cancer Biol 2002; 12:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan KC, Hung EC, Woo JK, et al. Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program. Cancer 2013; 119:1838.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan KCA, Woo JKS, King A, et al. Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer. N Engl J Med 2017; 377:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lou PJ, Jacky Lam WK, Hsu WL, et al. Performance and Operational Feasibility of Epstein-Barr Virus-Based Screening for Detection of Nasopharyngeal Carcinoma: Direct Comparison of Two Alternative Approaches. J Clin Oncol 2023; 41:4257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li T, Li F, Guo X, et al. Anti-Epstein-Barr Virus BNLF2b for Mass Screening for Nasopharyngeal Cancer. N Engl J Med 2023; 389:808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan AT, Ma BB, Lo YM, et al. Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. J Clin Oncol 2004; 22:3053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leung SF, Lo YM, Chan AT, et al. Disparity of sensitivities in detection of radiation-naïve and postirradiation recurrent nasopharyngeal carcinoma of the undifferentiated type by quantitative analysis of circulating Epstein-Barr virus DNA1,2. Clin Cancer Res 2003; 9:3431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang CL, Sun ZQ, Guo R, et al. Plasma Epstein-Barr Virus DNA Load After Induction Chemotherapy Predicts Outcome in Locoregionally Advanced Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys 2019; 104:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lv J, Chen Y, Zhou G, et al. Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma. Nat Commun 2019; 10:3941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leung SF, Chan KC, Ma BB, et al. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann Oncol 2014; 25:1204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan ATC, Hui EP, Ngan RKC, et al. Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. J Clin Oncol 2018; :JCO2018777847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim KY, Le QT, Yom SS, et al. Clinical Utility of Epstein-Barr Virus DNA Testing in the Treatment of Nasopharyngeal Carcinoma Patients. Int J Radiat Oncol Biol Phys 2017; 98:996.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3404 Version 36.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://gco.iarc.fr/" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Global Cancer Observatory. International Agency for Research on Cancer. World Health Organization. Available at: https://gco.iarc.fr/ (Accessed on December 13, 2023).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31178151" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Nasopharyngeal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17035381" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The enigmatic epidemiology of nasopharyngeal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17035381" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The enigmatic epidemiology of nasopharyngeal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12494479" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20-year period (1980-99): an encouraging reduction in both incidence and mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12450728" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Epidemiology of nasopharyngeal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16702360" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Difference in the incidence trend of nasopharyngeal and oropharyngeal carcinomas in Taiwan: implication from age-period-cohort analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26321262" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Nasopharyngeal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8824359" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Nasopharyngeal cancer in a low-risk population: defining risk factors by histological type.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24857071" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Epstein-Barr virus as a paradigm in nasopharyngeal cancer: from lab to clinic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22972969" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19336547" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Independent effect of EBV and cigarette smoking on nasopharyngeal carcinoma: a 20-year follow-up study on 9,622 males without family history in Taiwan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29072774" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Human papillomavirus and World Health Organization type III nasopharyngeal carcinoma: Multicenter study from an endemic area in Southern China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23780921" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma in a low-incidence population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24521676" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19296536" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Evaluation of nonviral risk factors for nasopharyngeal carcinoma in a high-risk population of Southern China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10216473" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Familial and sporadic cases of nasopharyngeal carcinoma in Taiwan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16415435" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Familial nasopharyngeal carcinoma in a cohort of 200 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12464650" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12516093" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Genetic susceptibility to nasopharyngeal carcinoma within the HLA-A locus in Taiwanese.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12118254" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15726104" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Further evidence for an HLA-related recessive mutation in nasopharyngeal carcinoma among the Chinese.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16377082" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Cytochrome P450 2A6 polymorphism in nasopharyngeal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16796765" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Polymorphisms of XRCC1 genes and risk of nasopharyngeal carcinoma in the Cantonese population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22245473" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34194007" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Nasopharyngeal carcinoma: an evolving paradigm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11190760" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The basaloid squamous cell carcinoma of the nasopharynx.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15950718" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Nasopharyngeal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10624338" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : MRI of local disease in nasopharyngeal carcinoma: tumour extent vs tumour stage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16769424" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Neurologic complications of head and neck cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6190547" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Nasopharyngeal carcinoma in Taiwan. Clinical manifestations and results of therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10213566" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Nasopharyngeal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7790274" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10030249" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Prognostic factors of nasopharynx tumors investigated by MR imaging and the value of MR imaging in the newly published TNM staging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18455329" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : How does magnetic resonance imaging influence staging according to AJCC staging system for nasopharyngeal carcinoma compared with computed tomography?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8246032" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Leukemoid reaction, bone marrow invasion, fever of unknown origin, and metastatic pattern in the natural history of advanced undifferentiated carcinoma of nasopharyngeal type: a review of 255 consecutive cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33358989" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17135642" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12419787" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15190138" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25997061" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30351466" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30192385" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18972431" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Comparison of 4 modalities for distant metastasis staging in endemic nasopharyngeal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23083522" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Accuracy of whole-body FDG-PET and FDG-PET/CT in M staging of nasopharyngeal carcinoma: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23857969" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23857969" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1309307" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4055129" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23255783" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Two Epstein-Barr virus-related serologic antibody tests in nasopharyngeal carcinoma screening: results from the initial phase of a cluster randomized controlled trial in Southern China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31373615" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10096545" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16002393" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12450734" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23436393" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28792880" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37478397" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Performance and Operational Feasibility of Epstein-Barr Virus-Based Screening for Detection of Nasopharyngeal Carcinoma: Direct Comparison of Two Alternative Approaches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37646678" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Anti-Epstein-Barr Virus BNLF2b for Mass Screening for Nasopharyngeal Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15284255" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12960133" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Disparity of sensitivities in detection of radiation-naïve and postirradiation recurrent nasopharyngeal carcinoma of the undifferentiated type by quantitative analysis of circulating Epstein-Barr virus DNA1,2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30682489" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Plasma Epstein-Barr Virus DNA Load After Induction Chemotherapy Predicts Outcome in Locoregionally Advanced Nasopharyngeal Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31477699" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24638904" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29989858" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28721913" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Clinical Utility of Epstein-Barr Virus DNA Testing in the Treatment of Nasopharyngeal Carcinoma Patients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
